Effects of all-trans retinoic acid on renin-angiotensin system in rats with experimental nephritis

被引:45
作者
Dechow, C
Morath, C
Peters, J
Lehrke, I
Waldherr, R
Haxsen, V
Ritz, E
Wagner, J
机构
[1] Heidelberg Univ, Dept Internal Med, Div Nephrol, D-69115 Heidelberg, Germany
[2] Heidelberg Univ, Div Pharmacol, D-69115 Heidelberg, Germany
关键词
anti-Thy1.1; nephritis; mesangioproliferative glomerulonephritis; candesartan; polymerase chain reaction; immunohistochemistry;
D O I
10.1152/ajprenal.2001.281.5.F909
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
We previously demonstrated that all-trans retinoic acid (RA) preserves glomerular structure and function in anti-Thy1.1 nephritis (Wagner J, Dechow C, Morath C, Lehrke I, Amann K, Floege J, and Ritz E. J Am Soc Nephrol 11: 1479-1489, 2000). Because the renin-angiotensin system (RAS) contributes to renal damage, we 1) studied retinoid-specific effects on its components and 2) compared the effects of all-trans-RA with those of the AT(1)-receptor blocker candesartan. Rats were pretreated for 3 days before injection of the OX-7 antibody and continued with treatment with either vehicle or daily injections of 10 mg/kg all-trans-RA only (study 1) or 10 mg/kg body wt all-trans-RA, 1 mg/kg candesartan, or both (study 2) for an additional 7 days. The blood pressure increase observed in anti-Thy1.1 nephritic rats was equally normalized by all-trans-RA and candesartan (P < 0.05). In nephritic rats, mRNAs of angiotensinogen and angiotensin-converting enzyme (ACE) in the kidney were unchanged, but renin mRNA was lower (P < 0.01). Renal and glomerular AT(1)-receptor gene and protein expression levels were higher in anti-Thy1.1 nephritic rats (P < 0.05). In the renal cortex of nephritic rats, pretreatment with all-trans-RA significantly reduced mRNAs of all the examined RAS components, but in the glomeruli it increased ACE gene and protein expression (P < 0.01). In nephritic rats, candesartan reduced the number of glomerular cells and mitoses (P < 0.05) less efficiently than all-trans-RA (P < 0.01). Both substances reduced cellular proliferation (proliferating cell nuclear antigen) significantly (P < 0.05). No additive effects were noted when both compounds were combined. In conclusion, all-trans-RA influences the renal RAS in anti-Thy1.1 nephritis by decreasing ANG II synthesis and receptor expression. The beneficial effect of retinoids may be explained, at least in part, by reduction of RAS activity.
引用
收藏
页码:F909 / F919
页数:11
相关论文
共 51 条
[31]  
MORATH C, IN PRESS J AM SOC NE
[32]   Mesangiolysis: An update [J].
Morita, T ;
Yamamoto, T ;
Churg, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :559-573
[33]  
Morsing P, 1999, J AM SOC NEPHROL, V10, pS248
[34]   NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats [J].
Muller, DN ;
Dechend, R ;
Mervaala, EMA ;
Park, JK ;
Schmidt, F ;
Fiebeler, A ;
Theuer, J ;
Breu, V ;
Ganten, D ;
Haller, H ;
Luft, FC .
HYPERTENSION, 2000, 35 (01) :193-201
[35]   Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis [J].
Nakamura, T ;
Obata, J ;
Kimura, H ;
Ohno, S ;
Yoshida, Y ;
Kawachi, H ;
Shimizu, F .
KIDNEY INTERNATIONAL, 1999, 55 (03) :877-889
[36]  
Nakamura T, 1997, KIDNEY INT, pS226
[37]   MESANGIAL CELL AUTOANTIGENS IN IMMUNOGLOBULIN-A NEPHROPATHY AND HENOCH-SCHONLEIN PURPURA [J].
ODONOGHUE, DJ ;
DARVILL, A ;
BALLARDIE, FW .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (05) :1522-1530
[38]  
ORTH SR, 1995, EXP NEPHROL, V3, P23
[39]   INCREASED ADRENAL RENIN IN TRANSGENIC HYPERTENSIVE RATS, TGR(MREN2)27, AND ITS REGULATION BY CAMP, ANGIOTENSIN-II, AND CALCIUM [J].
PETERS, J ;
MUNTER, K ;
BADER, M ;
HACKENTHAL, E ;
MULLINS, JJ ;
GANTEN, D .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (03) :742-747
[40]   Losartan and angiotensin II inhibit aldosterone production in anephric rats via different actions on the intraadrenal renin-angiotensin system [J].
Peters, J ;
Obermüller, N ;
Woyth, A ;
Peters, B ;
Maser-Gluth, C ;
Kränzlin, B ;
Gretz, N .
ENDOCRINOLOGY, 1999, 140 (02) :675-682